COMBINATION OF WEEKLY RADIATION AND DOCETAXEL FOR LOCALLY ADVANCED NON SMALL CA

每周放疗和多西紫杉醇相结合治疗局部晚期非小 CA

• 批准号: 7376351
• 负责人: PAUL O SCHWARZENBERGER
• 金额: $ 0.02万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376351
• 关键词: COMBINATION; WEEKLY; RADIATION; DOCETAXEL; LOCALLY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Locally advanced or unresectable non-small cell lung cancer (NSCLC) is considered an incurable disease with a life expectancy of less than two years regardless of treatment. Many patients with stage II and most with stage III NSCLC are initially controlled with surgery or radiation relapse at a remote site. This is believed to be due to the presence of malignant cells within the local tumor draining lymphatic system or at remote sites at the time of initial diagnosis. Local treatment modalities such as tumor irradiation as well as systemic chemotherapy have been clearly ineffective in controlling disease progression. Until recently, the benefit of treating locally advanced NSCLC has been controversial since some studies did not show improved survival over no treatment at all. Nevertheless, treatment was offered due to improved quality of life associated with treatment. Chemotherapy, radiation or both in succession are presently offered by most oncologist to these patients. It was hypothesized that both systemic and locoregional control of the disease could be improved by combining radiation and chemotherapy, subsequentially or concomitantly. This study aims to investigate if the combination of the drug Taxotere given one day before radiation is well tolerated and will result in enhanced shrinkage of the cancer as compared to traditional radiation therap

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。无论治疗如何，局部晚期或不可切除的非小细胞肺癌（NSCLC）被认为是一种无法治愈的疾病，预期寿命少于两年。许多患有II期和大多数III期NSCLC的患者最初在偏远部位通过手术或辐射复发控制。据信这是由于初始诊断时在局部肿瘤排出淋巴系统或偏远部位中存在恶性细胞所致。局部治疗方式，例如肿瘤照射以及全身化疗，在控制疾病进展方面显然无效。 直到最近，治疗本地高级NSCLC的好处一直存在争议，因为一些研究没有显示出任何治疗的生存率提高。然而，由于与治疗相关的生活质量的改善，提供了治疗。这些患者目前为这些患者提供了化学疗法，放射线或两者兼而有之。假设可以通过随后或同时将放射线和化学疗法组合来改善该疾病的全身和局部控制。这项研究旨在调查在辐射允许良好的前一天给出的药物遗传物的组合，并且与传统的放射线疗法相比，癌症的收缩率会增加。